Free tool
FAERS Monitor: Neurontin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020235 or its brand name (Neurontin, Gabapentin). Reports on generic versions are filed under their own applications.
Reports
364,199
Serious
231,729
64% of reports
Hospitalization
107,727
Death reported
34,539
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective29,887
- fatigue25,265
- nausea23,025
- pain21,365
- off label use20,051
- diarrhoea18,346
- headache18,088
- dizziness16,383
- fall15,680
- dyspnoea14,449
- vomiting12,290
- asthenia12,066
- pain in extremity11,693
- arthralgia11,623
- death11,274
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,727 |
| 2005 | 4,880 |
| 2006 | 4,578 |
| 2007 | 3,890 |
| 2008 | 3,697 |
| 2009 | 4,759 |
| 2010 | 7,706 |
| 2011 | 7,641 |
| 2012 | 10,961 |
| 2013 | 11,532 |
| 2014 | 14,043 |
| 2015 | 21,637 |
| 2016 | 25,871 |
| 2017 | 25,518 |
| 2018 | 30,289 |
| 2019 | 31,872 |
| 2020 | 27,335 |
| 2021 | 23,435 |
| 2022 | 22,063 |
| 2023 | 21,333 |
| 2024 | 20,663 |
| 2025 | 21,482 |
| 2026 | 15,281 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,689,960 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fallSignal | 15,680 | 2.8 | 2.8 | 17,643 |
| pain in extremitySignal | 11,693 | 2.3 | 2.3 | 8,786 |
| painSignal | 21,365 | 2.0 | 2.0 | 11,342 |
| dizziness | 16,383 | 1.9 | 1.9 | 7,241 |
| fatigue | 25,265 | 1.9 | 1.9 | 10,884 |
| asthenia | 12,066 | 1.9 | 1.8 | 4,910 |
| nausea | 23,025 | 1.7 | 1.7 | 6,702 |
| headache | 18,088 | 1.7 | 1.7 | 5,052 |
| diarrhoea | 18,346 | 1.7 | 1.6 | 4,826 |
| arthralgia | 11,623 | 1.6 | 1.6 | 2,821 |
| vomiting | 12,290 | 1.5 | 1.5 | 2,200 |
| dyspnoea | 14,449 | 1.5 | 1.5 | 2,303 |
| off label use | 20,051 | 1.3 | 1.3 | 1,673 |
| drug ineffective | 29,887 | 1.3 | 1.3 | 2,375 |
| death | 11,274 | 0.8 | 0.7 | 944 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.